Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus SOX for locally advanced gastric/GEJ adenocarcinoma
NCT05122091Phase 2Recruiting
- Sponsor
- Guangxi Medical University
- Start
- Nov 2021
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Guangxi Medical University. Started Nov 2021; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05122091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122091.